SCHEMBL9944620

SCHEMBL9944620

CCOC(C)c1ccc(C=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.55
ALDH1A3 P47895 2/20 0.46
ACHE P22303 6/20 0.44
PTGS2 P35354 6/20 0.44
BCHE P06276 5/20 0.44
ALDH1A1 P00352 6/20 0.42
ALDH3A1 P30838 1/20 0.42
CYP2A6 P11509 3/20 0.41
GRIA4 P48058 1/20 0.40
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2A13 Q16696 1/20 0.36
HSD17B10 Q99714 1/20 0.35
ALDH5A1 P51649 1/20 0.35
ABAT P80404 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338718 0.83 LMNA (0.43) ACHEPTGS2BCHELMNAMAPT
SCHEMBL895976 0.82 PTGS2 (0.62) TYRALDH1A3ACHEPTGS2BCHE
SCHEMBL1151204 0.81 ALDH1A1 (0.42) TYRACHEPTGS2BCHEALDH1A1
SCHEMBL6286470 0.79 TYR (0.48) TYRALDH1A3ACHEPTGS2BCHE
SCHEMBL13527943 0.79 ALDH1A1 (0.39) TYRALDH1A3ALDH1A1LMNAMAPT
Ethylene SCHEMBL6226363 0.78 LMNA (0.48) TYRALDH1A3ACHEPTGS2BCHE
SCHEMBL2047680 0.78 PTGS2 (0.53) TYRALDH1A3ACHEPTGS2BCHE
SCHEMBL9879225 0.78 PTGS2 (0.56) TYRALDH1A3ACHEPTGS2BCHE
SCHEMBL18253207 0.77 EPHX1 (0.44) TYRACHEPTGS2BCHELMNA
Cyclopropane SCHEMBL6228970 0.77 LMNA (0.46) TYRALDH1A3ACHEPTGS2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9901648-B2 Stabilization of biomolecules using sugar polymers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-02-27 US disclosed
US-9862709-B2 Processes for making compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-01-09 US disclosed
US-20150274710-A1 PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2015-10-01 US disclosed
US-9035053-B2 Processes for making compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-05-19 US disclosed
US-20140377838-A1 STABILIZATION OF BIOMOLECULES USING SUGAR POLYMERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-12-25 US disclosed
US-8846686-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-30 US disclosed
US-20140155439-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2014-06-05 US disclosed
US-20130303576-A1 ENZYME INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2013-11-14 US disclosed
US-20130184292-A1 Processes for Making Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-18 US disclosed
US-20130089625-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 US disclosed
US-20120149736-A1 ENZYME INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303576-A1 ENZYME INHIBITORS HDAC1, HDAC4, HDAC3 TYR 2879/4885ALDH1A3 333/4885ACHE 810/4885
US-20140155439-A1 ENZYME INHIBITORS HDAC4, HDAC1, HDAC3 TYR 3071/4885ALDH1A3 634/4885ACHE 1156/4885
US-20130184292-A1 Processes for Making Compounds Useful as Inhibitors of ATR Kinase ATR, ATRIP, CHEK1 TYR 978/4885ALDH1A3 3642/4885ACHE 3228/4885
US-20120149736-A1 ENZYME INHIBITORS HAT1, HDAC1, NAT1 TYR 2093/4885ALDH1A3 185/4885ACHE 652/4885
US-20140377838-A1 STABILIZATION OF BIOMOLECULES USING SUGAR POLYMERS TREH, HBG1, SMURF1 TYR 2044/4885ALDH1A3 2695/4885ACHE 2768/4885
US-20150274710-A1 PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, ATRIP, CHEK1 TYR 978/4885ALDH1A3 3642/4885ACHE 3228/4885
US-20130089625-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, MAP3K1 TYR 1572/4885ALDH1A3 4469/4885ACHE 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.